NCT04270175

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.

Conditions

• Amyloid
• AL Amyloidosis
• Refractory AL Amyloidosis

Interventions

Type	Name	Description
DRUG	Daratumumab SC	Given as 1800mg via injection
DRUG	Pomalidomide	Given as 4mg oral capsule
DRUG	Dexamethasone	Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.

Timeline

• Start date: 2021-04-14
• Primary completion: 2027-01-01
• Completion: 2028-01-01
• First posted: 2020-02-17
• Last updated: 2026-02-27

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study